Drug intelligence / Profile preview

CPT-SR01

Development stage: Preclinical
Lead developer: Enabled Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CPT-SR01 is a preclinical small molecule S1PR1 (sphingosine-1-phosphate receptor 1) modulator being developed by Mercaptor Discoveries for the treatment of multiple sclerosis and traumatic brain injury. The drug is part of Mercaptor's "Capton" platform, which utilizes molecules designed to remain inactive until they reach tissues experiencing oxidative stress, such as those affected by neuroinflammation or trauma. By targeting S1PR1, CPT-SR01 aims to modulate immune cell trafficking and provide neuroprotective effects while minimizing systemic side effects through its site-specific activation mechanism.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on CPT-SR01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPT-SR01.

Explore the full profile